These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 9879479)

  • 1. [Treatment of androgenetic alopecia in the man using systemic 5 alpha-reductase inhibition].
    Wolff H; Kunte C
    Hautarzt; 1998 Nov; 49(11):813-7. PubMed ID: 9879479
    [No Abstract]   [Full Text] [Related]  

  • 2. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia.
    Suchonwanit P; Srisuwanwattana P; Chalermroj N; Khunkhet S
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2257-2263. PubMed ID: 29972712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guidelines on the use of finasteride in androgenetic alopecia.
    Mysore V; Shashikumar BM
    Indian J Dermatol Venereol Leprol; 2016; 82(2):128-34. PubMed ID: 26924401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guidelines for the management of androgenetic alopecia (2010).
    Tsuboi R; Itami S; Inui S; Ueki R; Katsuoka K; Kurata S; Kono T; Saito N; Manabe M; Yamazaki M;
    J Dermatol; 2012 Feb; 39(2):113-20. PubMed ID: 22171995
    [No Abstract]   [Full Text] [Related]  

  • 5. Dutasteride in Androgenetic Alopecia: An Update.
    Arif T; Dorjay K; Adil M; Sami M
    Curr Clin Pharmacol; 2017; 12(1):31-35. PubMed ID: 28294070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse Effects of 5-Alpha Reductase Inhibitor Therapy in Men With Androgenetic Alopecia: Is There Cause for Concern?
    Arias-Santiago S; Camacho-Martínez FM
    Actas Dermosifiliogr; 2016 Nov; 107(9):709-711. PubMed ID: 27436801
    [No Abstract]   [Full Text] [Related]  

  • 7. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.
    Gubelin Harcha W; Barboza Martínez J; Tsai TF; Katsuoka K; Kawashima M; Tsuboi R; Barnes A; Ferron-Brady G; Chetty D
    J Am Acad Dermatol; 2014 Mar; 70(3):489-498.e3. PubMed ID: 24411083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depression circumstantially related to the administration of finasteride for androgenetic alopecia.
    Altomare G; Capella GL
    J Dermatol; 2002 Oct; 29(10):665-9. PubMed ID: 12433001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis.
    Lee S; Lee YB; Choe SJ; Lee WS
    Acta Derm Venereol; 2019 Jan; 99(1):12-17. PubMed ID: 30206635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of efficacy and safety of finasteride 1 mg in 3177 Japanese men with androgenetic alopecia.
    Sato A; Takeda A
    J Dermatol; 2012 Jan; 39(1):27-32. PubMed ID: 21980923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgenetic alopecia; drug safety and therapeutic strategies.
    Motofei IG; Rowland DL; Baconi DL; Tampa M; Sârbu MI; Păunică S; Constantin VD; Bălălău C; Păunică I; Georgescu SR
    Expert Opin Drug Saf; 2018 Apr; 17(4):407-412. PubMed ID: 29363345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic hotline. Treatment of androgenic alopecia with finasteride may result in a high grade prostate cancer in patients: fact or fiction?
    Lynn R; Krunic A
    Dermatol Ther; 2010; 23(5):544-6. PubMed ID: 20868409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Finasteride for female androgenetic alopecia.
    Thai KE; Sinclair RD
    Br J Dermatol; 2002 Oct; 147(4):812-3. PubMed ID: 12366441
    [No Abstract]   [Full Text] [Related]  

  • 14. Secondary infertility due to use of low-dose finasteride.
    Şalvarci A; Istanbulluoğlu O
    Int Urol Nephrol; 2013 Feb; 45(1):83-5. PubMed ID: 23070721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride.
    Gupta AK; Charrette A
    J Dermatolog Treat; 2014 Apr; 25(2):156-61. PubMed ID: 23768246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Finasteride in the treatment of alopecia.
    Libecco JF; Bergfeld WF
    Expert Opin Pharmacother; 2004 Apr; 5(4):933-40. PubMed ID: 15102575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sexual dysfunction with 5-alpha-reductase inhibitor therapy for androgenetic alopecia: A global propensity score matched retrospective cohort study.
    Lauck KC; Limmer A; Harris P; Kivelevitch D
    J Am Acad Dermatol; 2024 Jul; 91(1):163-166. PubMed ID: 38552905
    [No Abstract]   [Full Text] [Related]  

  • 18. [Androgenetic alopecia. Denser hair growth on two-thirds of balding scalps].
    MMW Fortschr Med; 2000 May; 142(20):63. PubMed ID: 10870400
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of finasteride 1 mg in the treatment of androgenetic alopecia in men.
    Olsen EA
    Exp Dermatol; 1999 Aug; 8(4):302-3. PubMed ID: 10439233
    [No Abstract]   [Full Text] [Related]  

  • 20. Advances in the treatment of male androgenetic alopecia: a brief review of finasteride studies.
    Whiting DA
    Eur J Dermatol; 2001; 11(4):332-4. PubMed ID: 11399540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.